Study identifier:D9673R00028
ClinicalTrials.gov identifier:NCT05573893
EudraCT identifier:N/A
CTIS identifier:N/A
Prospective non-interventional study (NIS) to examine the impact of eHealth support on patient-reported outcomes and on real world clinical data in patients with HER2-positive unresectable or metastatic breast cancer treated with Trastuzumab Deruxtecan
Breast Neoplasms
N/A
No
-
All
390
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 May 2023 by AstraZeneca
AstraZeneca
Daiichi Sankyo
No locations available
Arms | Assigned Interventions |
---|---|
Cohort 1 Cohort 1 containing patients with documentation of a CANKADO PRO-React Onco questionnaire on at least 30 days during the first 90 days after activating/ first usage of the DiGA within the study. | - |
Cohort 2 Cohort 2 containing patients with documentation of a CANKADO PRO-React Onco questionnaire on less than 30 days during the first 90 days after activating/ first usage of the DiGA within the study or having stated at baseline to decline CANKADO PRO-React Onco usage. | - |